Lb Pharmaceuticals (LBRX) Interest & Investment Income (2024 - 2026)

Lb Pharmaceuticals' Interest & Investment Income history runs 3 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 1107.63% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $6.6 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, up 127.77% from the prior year.
• Interest & Investment Income was $2.8 million for Q1 2026 at Lb Pharmaceuticals, up from $2.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q1 2026 to a low of $236000.0 in Q1 2025.
• Historically, Interest & Investment Income has averaged $1.2 million across 3 years, with a median of $545500.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income soared 84.11% in 2025, then surged 1107.63% in 2026.
• A 3-year view of Interest & Investment Income shows it stood at $298000.0 in 2024, then surged by 839.6% to $2.8 million in 2025, then increased by 1.79% to $2.8 million in 2026.
• The last three Interest & Investment Income figures came in at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $707000.0 (Q3 2025), per Business Quant data.